Literature DB >> 12749321

A case of relapsing neuromyelitis optica treated with glatiramer acetate.

Roberto Bergamaschi, Carla Uggetti, Simone Tonietti, Maria Grazia Egitto, Vittorio Cosi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12749321     DOI： 10.1007/s00415-003-0979-2

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  12 in total

1.  Treatment of neuromyelitis optica: current debate.

Authors:  Tomoko Okamoto; Masafumi Ogawa; Youwei Lin; Miho Murata; Sachiko Miyake; Takashi Yamamura
Journal:  Ther Adv Neurol Disord       Date:  2008-07       Impact factor: 6.570

2.  Immune agents for the treatment of Devic's neuromyelitis optica.

Authors:  R Bergamaschi
Journal:  Neurol Sci       Date:  2007-10       Impact factor: 3.307

3.  Practice current: How do you treat neuromyelitis optica?

Authors:  Aravind Ganesh
Journal:  Neurol Clin Pract       Date:  2017-04

4.  [Diagnosis and treatment of neuromyelitis optica. Consensus recommendations of the Neuromyelitis Optica Study Group].

Authors:  C Trebst; A Berthele; S Jarius; T Kümpfel; S Schippling; B Wildemann; C Wilke
Journal:  Nervenarzt       Date:  2011-06       Impact factor: 1.214

5.  Current and future treatment approaches for neuromyelitis optica.

Authors:  Nicolas Collongues; Jérôme de Seze
Journal:  Ther Adv Neurol Disord       Date:  2011-03       Impact factor: 6.570

Review 6.  Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders.

Authors:  Ingo Kleiter; Ralf Gold
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 7.  [Neuromyelitis optica].

Authors:  S Jarius; B Wildemann
Journal:  Nervenarzt       Date:  2007-12       Impact factor: 1.214

8.  Neuromyelitis Optica.

Authors:  Dean M Wingerchuk; Brian G Weinshenker
Journal:  Curr Treat Options Neurol       Date:  2005-05       Impact factor: 3.972

9.  Idiopathic transverse myelitis and neuromyelitis optica: clinical profiles, pathophysiology and therapeutic choices.

Authors:  Amer Awad; Olaf Stüve
Journal:  Curr Neuropharmacol       Date:  2011-09       Impact factor: 7.363

10.  Neuromyelitis optica: an antibody-mediated disorder of the central nervous system.

Authors:  Jiwon Oh; Michael Levy
Journal:  Neurol Res Int       Date:  2012-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.